摘要
目的探讨手术联合化学疗法治疗非小细胞肺癌(NSCLC)的临床效果及其对血清内皮抑素(ES)水平的影响。方法 68例NSCLC患者根据治疗方案不同分为观察组和对照组,每组34例,观察组患者给予手术联合化学治疗,对照组患者仅手术治疗。比较2组患者的近期疗效及治疗前后血清ES水平。结果观察组和对照组治疗总有效率分别为76.47%和44.12%,观察组患者治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前2组患者血清ES水平比较差异无统计学意义(P>0.05);治疗后2组患者血清ES水平均显著高于治疗前,差异有统计学意义(P<0.05);治疗后观察组患者血清ES水平显著高于对照组,差异有统计学意义(P<0.05)。观察组患者发生胃肠道反应19例,骨髓抑制23例,经对症及支持治疗后好转;2组患者均无严重不良反应发生。结论手术联合化学治疗可显著提高NSCLC患者血清ES水平,疗效显著,且不良反应少。
Objective To investigate the effect of surgery combined with chemotherapy in treatment of patients with nonsmall-cell lung cancer（ NSCLC） and its effect on the level of serum endostatin（ ES）. Methods Sixty-eight patients with NSCLC were divided into observation group and control group according to therapeutic regimen,thirty-four cases in each group. The patients in observation group were treated with surgery and chemotherapy,while the patients in control group were treated with surgery. The recent effect and serum ES level were compared between the two groups. Results The total effective rate in observation group and control group was 76. 47% and 44. 12% respectively,the total effective rate in observation group was significantly higher than that in control group（ P 0. 05）. There was no significant difference in serum ES level before treatment between the two groups（ P 0. 05）. The serum ES level after treatment was significantly higher than that before treatment in the two groups（ P 0. 05）. After treatment,the serum ES level in observation group was significantly higher than that in control group（ P 0. 05）. Nineteen patients with gastrointestinal reaction and twenty-three patients with myelosuppression in observation group were improved after symptomatic treatment and supportive treatment. There was no severe adverse effect in the two groups. Conclusion Surgery combined with chemotherapy for treating NSCLC has the significant effect with less adverse effect,and can significantly improve the level of serum ES.
出处
《新乡医学院学报》
CAS
2014年第6期443-445,共3页
Journal of Xinxiang Medical University
关键词
手术
化学治疗
内皮抑素
非小细胞肺癌
surgery chemotherapy endostatin nonsmall-cell lung cancer
